quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:38:45·50d
INSIDERFiling
Recursion Pharmaceuticals Inc. logo

Director Borgeson Blake sold $588,200 worth of shares (170,000 units at $3.46), decreasing direct ownership by 3% to 6,259,863 units (SEC Form 4)

RXRX· Recursion Pharmaceuticals Inc.
Health Care
Original source

Companies

  • RXRX
    Recursion Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Dec 17UpdateAnalyst$11.00
  • Jul 3UpdateMorgan Stanley$5.00
  • May 22UpdateMorgan Stanley$8.00
  • Mar 16UpdateNeedham$17.00
  • Sep 16UpdateKeyBanc Capital Markets$20.00
  • Apr 18UpdateBofA Securities$10.00

Related

  • INSIDER15d
    SEC Form 4 filed by Taylor Ben R
  • INSIDER15d
    SEC Form 4 filed by Gibson Christopher
  • INSIDER15d
    SEC Form 4 filed by Borgeson Blake
  • PR17d
    Recursion to Participate in Upcoming Investor Conferences
  • INSIDER21d
    SEC Form 4 filed by Dar Zavain
  • INSIDER21d
    SEC Form 4 filed by Li Dean Y
  • PR24d
    Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022